| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Innate Pharma SA
13D/A
45781K105
|
8.3% |
2/6/2026
Event 12/22/2025
|
||||
| AstraZeneca PLC | 8.3% | |||||
| MedImmune Limited | 8.3% | |||||
|
Cellectis S.A.
13D/A
CLLS · 15117K103
|
44.0% |
1/24/2025
Event 1/23/2025
|
||||
| AstraZeneca PLC | 44.0% | |||||
| AstraZeneca Holdings B.V. | 44.0% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Monopar Therapeutics Inc.
13G/A
MNPR · 61023L207
|
7.8% |
2/6/2026
Event 12/31/2025
|
||||
| AstraZeneca PLC | 7.8% | |||||
| Alexion Pharmaceuticals, Inc. | 7.8% | |||||
|
Conduit Pharmaceuticals Inc.
13G/A
CDT · 20678X106
|
1.1% |
4/10/2025
Event 3/31/2025
|
||||
| AstraZeneca PLC | 1.1% | |||||
| AstraZeneca AB | 1.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.